Linax E 5/10 mg is a combination oral antidiabetic medication containing Linagliptin, a DPP-4 inhibitor, and Empagliflozin, an SGLT2 inhibitor. This dual-action formula enhances glycemic control in adults with type 2 diabetes mellitus by:
Linagliptin: Inhibits the DPP-4 enzyme, increasing incretin hormone levels, which boost insulin secretion and suppress glucagon release in a glucose-dependent manner.
Empagliflozin: Blocks the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting urinary glucose excretion.